LianBio Announces Clinical Supply Agreement with AstraZeneca in China to Evaluate BBP-398 in Combination with Osimertinib in Patients with Non-Small Cell Lung Cancer with EGFR Mutations

data-ke-size="size16">LianBio, a biotechnology company committed to bringing innovative medicines to patients in China and other major Asian markets, has recently announced a clinical supply agreement with AstraZeneca in China. The purpose of this agreement is to assess the safety and effectiveness of BBP-398, an investigational SHP2 inhibitor, when used in combination with AstraZeneca's osimert..